CN101257923A - 用于癌症治疗的抗ccr7受体的抗体 - Google Patents

用于癌症治疗的抗ccr7受体的抗体 Download PDF

Info

Publication number
CN101257923A
CN101257923A CNA2006800323035A CN200680032303A CN101257923A CN 101257923 A CN101257923 A CN 101257923A CN A2006800323035 A CNA2006800323035 A CN A2006800323035A CN 200680032303 A CN200680032303 A CN 200680032303A CN 101257923 A CN101257923 A CN 101257923A
Authority
CN
China
Prior art keywords
ccr7
cells
antibody
tumor cells
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800323035A
Other languages
English (en)
Chinese (zh)
Inventor
塞西莉亚·穆尼奥斯卡列哈
曼努埃尔·赫苏斯·阿方索佩雷斯
索尼亚·洛佩斯希拉尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Autonoma de Madrid
Original Assignee
Universidad Autonoma de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Autonoma de Madrid filed Critical Universidad Autonoma de Madrid
Publication of CN101257923A publication Critical patent/CN101257923A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA2006800323035A 2005-07-06 2006-07-05 用于癌症治疗的抗ccr7受体的抗体 Pending CN101257923A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2005/007371 WO2007003216A1 (en) 2005-07-06 2005-07-06 Anti-ccr7 receptor antibodies for the treatment of cancer
EPPCT/EP2005/007371 2005-07-06

Publications (1)

Publication Number Publication Date
CN101257923A true CN101257923A (zh) 2008-09-03

Family

ID=36021798

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800323035A Pending CN101257923A (zh) 2005-07-06 2006-07-05 用于癌症治疗的抗ccr7受体的抗体

Country Status (16)

Country Link
US (1) US8066996B2 (enExample)
EP (1) EP1904102B1 (enExample)
JP (1) JP5249025B2 (enExample)
KR (1) KR20080030655A (enExample)
CN (1) CN101257923A (enExample)
AT (1) ATE453407T1 (enExample)
AU (1) AU2006265281C1 (enExample)
BR (1) BRPI0612632A2 (enExample)
CA (1) CA2614080C (enExample)
DE (1) DE602006011466D1 (enExample)
DK (1) DK1904102T3 (enExample)
ES (1) ES2338919T3 (enExample)
IL (1) IL188594A (enExample)
PT (1) PT1904102E (enExample)
RU (1) RU2404808C2 (enExample)
WO (2) WO2007003216A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103261412A (zh) * 2010-09-28 2013-08-21 积水化学工业株式会社 抗人ccr7 抗体、杂交瘤、核酸、载体、细胞、医药组合物和抗体固定化担载体
TWI839325B (zh) * 2017-02-03 2024-04-21 瑞士商諾華公司 抗體藥物結合物

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006213686A1 (en) 2005-02-09 2006-08-17 Avi Bio Pharma, Inc. Antisense composition and method for treating muscle atrophy
EP2285403A2 (en) * 2008-05-14 2011-02-23 Msm Protein Technologies, Inc. Human monoclonal antibodies against human chemokine receptor ccr7
US9101559B2 (en) 2009-05-08 2015-08-11 New York University Leukemic cell CNS infiltration controlled by notch-induced chemotaxis
WO2011040428A1 (ja) * 2009-09-29 2011-04-07 学校法人慶應義塾 抗腫瘍剤およびそのスクリーニング方法
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
WO2014151834A2 (en) 2013-03-15 2014-09-25 Amgen Inc. Methods and compositions relating to anti-ccr7 antigen binding proteins
WO2015147335A1 (ja) * 2014-03-27 2015-10-01 国立大学法人大阪大学 脳マラリアの診断および治療
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
BR112018002877A2 (pt) 2015-08-10 2018-11-06 anticorpos anti-receptor ccr7 humanizados
MA45819A (fr) 2015-10-09 2018-08-15 Sarepta Therapeutics Inc Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof
KR20210132644A (ko) * 2018-12-18 2021-11-04 캐터펄트 테라퓨틱스 비.브이. 이식편 대 숙주 질환(GvHD)의 예방 또는 치료를 위한 항-CCR7 mAb의 용도
US20230181756A1 (en) * 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
CN119390838B (zh) * 2024-05-29 2025-06-10 锐胜科生物医药(上海)有限公司 一种靶向ccr7的纳米抗体及其制备与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
FR2818747B1 (fr) * 2000-12-26 2003-05-16 Molecular Engines Laboratoires Procede de criblage base sur l'interaction siah-numb
US20020168358A1 (en) * 2001-04-30 2002-11-14 Gladue Ronald P. Treatment of T-cell mediated diseases
DE10248751A1 (de) * 2002-10-18 2004-05-06 Berdel, Wolfgang E., Prof. Dr.med. Dyslokalisationsmoleküle und deren Verwendung
WO2004104574A2 (en) * 2003-05-23 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
CA2529058A1 (en) * 2003-06-11 2005-01-13 The University Of Chicago Increased t-cell tumor infiltration by mutant light

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103261412A (zh) * 2010-09-28 2013-08-21 积水化学工业株式会社 抗人ccr7 抗体、杂交瘤、核酸、载体、细胞、医药组合物和抗体固定化担载体
CN105884895A (zh) * 2010-09-28 2016-08-24 积水化学工业株式会社 抗人ccr7抗体、杂交瘤、核酸、载体、细胞、医药组合物和抗体固定化担载体
CN105884895B (zh) * 2010-09-28 2019-12-13 株式会社Nb健康研究所 抗人ccr7抗体、杂交瘤、核酸、载体、细胞、医药组合物和抗体固定化担载体
TWI839325B (zh) * 2017-02-03 2024-04-21 瑞士商諾華公司 抗體藥物結合物

Also Published As

Publication number Publication date
CA2614080C (en) 2014-08-26
EP1904102B1 (en) 2009-12-30
EP1904102A1 (en) 2008-04-02
IL188594A (en) 2012-02-29
US20090123483A1 (en) 2009-05-14
BRPI0612632A2 (pt) 2012-01-03
US8066996B2 (en) 2011-11-29
JP5249025B2 (ja) 2013-07-31
JP2008545000A (ja) 2008-12-11
DE602006011466D1 (de) 2010-02-11
WO2007003426A1 (en) 2007-01-11
PT1904102E (pt) 2010-03-29
RU2008104420A (ru) 2009-08-20
DK1904102T3 (da) 2010-04-19
AU2006265281C1 (en) 2012-11-15
RU2404808C2 (ru) 2010-11-27
IL188594A0 (en) 2008-04-13
WO2007003216A1 (en) 2007-01-11
ATE453407T1 (de) 2010-01-15
CA2614080A1 (en) 2007-01-11
AU2006265281B2 (en) 2012-03-01
KR20080030655A (ko) 2008-04-04
ES2338919T3 (es) 2010-05-13
AU2006265281A1 (en) 2007-01-11

Similar Documents

Publication Publication Date Title
US11845792B2 (en) Epitope specific antibodies that bind cell surface GRP78 and their use for cancer detection
IL188594A (en) Anti-ccr7 receptor antibodies for the treatment of cancer
CN109069620B (zh) 拮抗剂ccr7受体的人源化抗体
KR102048718B1 (ko) 항-cxcr4 항체 및 항체-약물 접합체
ES2550621T3 (es) Anticuerpos anti-CD19 y usos en oncología
KR102338832B1 (ko) Ccr9에 대한 항체 및 그의 적용방법
CN1981868A (zh) 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
AU2002236519A1 (en) Methods for the prevention and treatment of cancer using anti-C3B(i) antibodies
CN105579058A (zh) Cd38激动剂的医学用途
JP2021510299A (ja) 抗体の新規組み合わせおよびその使用
IL278522B2 (en) Methods for treating cancer with a combination of anti-PD-1 antibody and always an anti-tissue factor antibody drug
CN101553259A (zh) 显示cd63表面表达的细胞的细胞毒性介导
HK1124760A (en) Anti-ccr7 receptor antibodies for the treatment of cancer
HK1255020A1 (en) Humanized anti-ccr7 receptor antibodies
HK1255020B (en) Humanized anti-ccr7 receptor antibodies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1124760

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080903

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1124760

Country of ref document: HK